A once-daily oral therapy targeting neutrophilic inflammation has shown promise in reducing exacerbations in patients with ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

A phase 3 clinical trial reports that nerandomilast was associated with a smaller decline in forced vital capacity in ...

A 2024 nationwide survey of French ICUs reveals critical gaps in managing invasive candidiasis, including underutilization of ...

Presented at EuroPCR 2025, the 10-year results of the DANAMI-3-PRIMULTI trial show how complete revascularisation cuts ...

Discover a Phase 3 trial that evaluated stapokibart as an additional therapy for adults with moderate-to-severe seasonal ...